Drug search by name

Ocrelizumab Intravenous and Zostavax

Determining the interaction of Ocrelizumab Intravenous and Zostavax and the possibility of their joint administration.

Check result:

Ocrelizumab Intravenous <> Zostavax

Relevance: 07.05.2022 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

If you are currently being treated or have recently been treated with ocrelizumab, you should let your doctor know before receiving zoster vaccine live. Depending on the dose and length of time you have been on ocrelizumab, you may be at risk for developing an infection from the vaccine or have a reduced response to the vaccine. In some situations, your doctor may want to delay vaccination to give your body time to recover from the effects of ocrelizumab therapy. If you have recently been vaccinated with zoster vaccine live, your doctor may choose to postpone treatment with ocrelizumab for 6 weeks. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

GENERALLY AVOID: The administration of live, attenuated virus or bacterial vaccines during immunosuppressant therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. There are currently no data on the secondary transmission of infection by these vaccines in patients receiving ocrelizumab specifically. Immunosuppressed patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.

MANAGEMENT: Live virus or bacterial vaccines should not be used in patients receiving ocrelizumab therapy. Vaccination should be deferred until after such therapy has been discontinued and there is B-cell repletion. Ocrelizumab labeling recommends that all immunizations be administered according to current immunization guidelines at least 6 weeks prior to initiating ocrelizumab treatment.

References

Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. "Harrison's Principles of Internal Medicine. 14th ed." New York, NY: McGraw-Hill Health Professionals Division (1998):
CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18
"Product Information. Ocrevus (ocrelizumab)." Genentech, South San Francisco, CA.

Ocrelizumab Intravenous

Generic Name: ocrelizumab

Brand name: Ocrevus

Synonyms: Ocrelizumab (Intravenous), Ocrelizumab

What is Ocrelizumab Intravenous?

Zostavax

Generic Name: zoster vaccine live

Brand name: Zostavax

Synonyms: n.a.

What is Zostavax?

+ Add a drug Remove all

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

The list of popular interactions